206 related articles for article (PubMed ID: 23760495)
1. Evaluation of a reductively activated duocarmycin prodrug against murine and human solid cancers.
Vielhauer GA; Swink M; Parelkar NK; Lajiness JP; Wolfe AL; Boger D
Cancer Biol Ther; 2013 Jun; 14(6):527-36. PubMed ID: 23760495
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activation.
Lajiness JP; Robertson WM; Dunwiddie I; Broward MA; Vielhauer GA; Weir SJ; Boger DL
J Med Chem; 2010 Nov; 53(21):7731-8. PubMed ID: 20942408
[TBL] [Abstract][Full Text] [Related]
3. A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct.
Wolfe AL; Duncan KK; Parelkar NK; Weir SJ; Vielhauer GA; Boger DL
J Med Chem; 2012 Jun; 55(12):5878-86. PubMed ID: 22650244
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
5. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
6. A unique class of duocarmycin and CC-1065 analogues subject to reductive activation.
Jin W; Trzupek JD; Rayl TJ; Broward MA; Vielhauer GA; Weir SJ; Hwang I; Boger DL
J Am Chem Soc; 2007 Dec; 129(49):15391-7. PubMed ID: 18020335
[TBL] [Abstract][Full Text] [Related]
7. Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.
Wolfe AL; Duncan KK; Parelkar NK; Brown D; Vielhauer GA; Boger DL
J Med Chem; 2013 May; 56(10):4104-15. PubMed ID: 23627265
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
Qu Y; Zhang C; Ma X; Gao Y; Liu J; Wu L
Bioorg Med Chem; 2020 Dec; 28(24):115821. PubMed ID: 33091789
[TBL] [Abstract][Full Text] [Related]
9. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.
Wilson WR; Stribbling SM; Pruijn FB; Syddall SP; Patterson AV; Liyanage HD; Smith E; Botting KJ; Tercel M
Mol Cancer Ther; 2009 Oct; 8(10):2903-13. PubMed ID: 19808982
[TBL] [Abstract][Full Text] [Related]
10. Duocarmycin-based prodrugs for cancer prodrug monotherapy.
Tietze LF; Schuster HJ; Schmuck K; Schuberth I; Alves F
Bioorg Med Chem; 2008 Jun; 16(12):6312-8. PubMed ID: 18524605
[TBL] [Abstract][Full Text] [Related]
11. Targeted cancer cell delivery of arsenate as a reductively activated prodrug.
Cioloboc D; Kurtz DM
J Biol Inorg Chem; 2020 May; 25(3):441-449. PubMed ID: 32189144
[TBL] [Abstract][Full Text] [Related]
12. A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models.
Spangler B; Fontaine SD; Shi Y; Sambucetti L; Mattis AN; Hann B; Wells JA; Renslo AR
J Med Chem; 2016 Dec; 59(24):11161-11170. PubMed ID: 27936709
[TBL] [Abstract][Full Text] [Related]
13. 5-Fluoroindole-3-acetic acid: a prodrug activated by a peroxidase with potential for use in targeted cancer therapy.
Folkes LK; Greco O; Dachs GU; Stratford MR; Wardman P
Biochem Pharmacol; 2002 Jan; 63(2):265-72. PubMed ID: 11841802
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antitumor activity of CBI-bearing ester and carbamate prodrugs of CC-1065 analogue.
Wang Y; Li L; Tian Z; Jiang W; Larrick JW
Bioorg Med Chem; 2006 Dec; 14(23):7854-61. PubMed ID: 16908174
[TBL] [Abstract][Full Text] [Related]
15. Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma.
Rango E; D'Antona L; Iovenitti G; Brai A; Mancini A; Zamperini C; Trivisani CI; Marianelli S; Fallacara AL; Molinari A; Cianciusi A; Schenone S; Perrotti N; Dreassi E; Botta M
Eur J Med Chem; 2021 Nov; 223():113653. PubMed ID: 34161866
[TBL] [Abstract][Full Text] [Related]
16. Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy.
Sundarraj S; Thangam R; Sujitha MV; Vimala K; Kannan S
Toxicol Appl Pharmacol; 2014 Mar; 275(3):232-43. PubMed ID: 24467950
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonamidate clodronate prodrug exhibits selective cytotoxic activity against melanoma cell lines.
Webster MR; Kamat C; Connis N; Zhao M; Weeraratna AT; Rudek MA; Hann CL; Freel Meyers CL
Mol Cancer Ther; 2014 Feb; 13(2):297-306. PubMed ID: 24310621
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
20. Initial development of a cytotoxic amino-seco-CBI warhead for delivery by prodrug systems.
Twum EA; Nathubhai A; Wood PJ; Lloyd MD; Thompson AS; Threadgill MD
Bioorg Med Chem; 2015 Jul; 23(13):3481-9. PubMed ID: 25963825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
